4.5 Review

Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: A systematic review and meta-analysis

期刊

HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 11, 期 6, 页码 1418-1425

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2015.1011996

关键词

adverse reaction rate; children; fundamental immunity; infants; Japanese encephalitis vaccines; meta-analysis; seroconversion rate; JE; Japanese encephalitis; JEV-I; Japanese encephalitis inactivated vaccine; JEV-L; Japanese encephalitis live-attenuated vaccine; JEV-I(Vero); Japanese encephalitis inactivated vaccine (Vero cell); JEV-I(PHK); Japanese encephalitis inactivated vaccine (Primary Hamster Kidney cell); JEV-PIV; Japanese encephalitis purified inactivated vaccine (Vero cell-derived SA14-14-2 strain); JE-SV; JE subunit vaccine; RCT; randomized controlled trial; RR; relative risk

资金

  1. Important National Science & Technology Specific Projects [2011ZX 1004-902]

向作者/读者索取更多资源

Japanese encephalitis virus (JEV), a leading cause of Japanese encephalitis (JE) in children and adults, is a major public health problem in Asian countries. This study reports a meta-analysis of the immunogenicity and safety of vaccines used to protect infants or children from JE. Three types of JE vaccine were examined, namely, Japanese encephalitis live-attenuated vaccine (JEV-L), Japanese encephalitis inactivated vaccine (Vero cell) (JEV-I(Vero)), and Japanese encephalitis inactivated vaccine (primary hamster kidney cell) (JEV-I(PHK)). These vaccines are used to induce fundamental immunity against JE; however, few studies have compared their immunogenicity and safety in infants and young children less than 2years of age. Data were obtained by searching 5 databases: Web of Science, PubMed, China National Knowledge Infrastructure, the China Wanfang database, and the Cochrane database. Fifteen articles were identified and scored using the Jadad score for inclusion in the meta-analysis. Random effect models were used to calculate the pooled seroconversion rate and adverse reaction rate when tests for heterogeneity were significant. The results showed that the pooled seroconversion rate for JEV-I(PHK) (62.23%) was lower than that for JEV-I(Vero) (86.49%) and JEV-L (83.52%), and that the pooled adverse reaction rate for JEV-L (18.09%) was higher than that for JEV-I(PHK) (10.08%) and JEV-I(Vero) (12.49%). The pooled relative risk was then calculated to compare the seroconversion and adverse reaction rates. The results showed that JEV-I(Vero) and JEV-L were more suitable than JEV-I(PHK) for inducing fundamental immunity to JE in infants and children less than 2years of age.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据